Ulerythema

Back

Background

Ulerythema ophryogenes, a rare cutaneous disorder, is characterized by inflammatory keratotic facial papules that may result in scars, atrophy, and alopecia. This disorder has been described in association with other congenital anomalies such as Noonan syndrome, de Lange syndrome, and Rubinstein-Taybi syndrome.[1, 2, 3, 4] Ulerythema ophryogenes falls within the broader category of keratosis pilaris atrophicans.[5] It was suggested to link this category with lichen planopilaris under the rubric of an even broader grouping, lichenoid folliculitis.[6]

In 1889, Tancer introduced the term ulerythema ophryogenes. In 1892, Unna coined the term. In 1925, Gans used the designation keratosis pilaris rubra atrophicans faciei.

Pathophysiology

Ulerythema ophryogenes is a relatively infrequent disorder that mainly affects children and young adults. It is usually sporadic, although cases inherited in an autosomal dominant pattern also are described. Although the condition is benign, it is still worrisome for parents. The inclusion of ulerythema ophryogenes into the concept of pilar keratoses has been proposed. Griffiths proposes the inclusion into the broader concept of keratosis pilaris atrophicans, while Dawber proposes the inclusion into scarring follicular keratosis.

Genetic factors are important. There appears to be an association between the syndrome of partial monosomy of the short arm of chromosome 18 and the genodermatoses keratosis pilaris and ulerythema ophryogenes,[7] which could be viewed as a new rare syndrome.[8] A few patients have been described, suggesting this linkage. The genes responsible for follicular keratinization could be located on the short arm of this chromosome. Most patients with cardiofaciocutaneous syndrome exhibit keratosis pilaris and ulerythema ophryogenes[9] , in one survey 82% having the former and 44% the latter, out of 45 patients.[10]

Etiology

The true cause of ulerythema ophryogenes remains unknown. In a few families, this disorder is inherited in an autosomal dominant pattern. A molecular defect has so far not been elucidated, but certain clues are emerging as ulerythema appears as a trait in different syndromes.

Possible molecular defects are mentioned in ulerythema ophryogenes associated with more serious conditions such as Cornelia de Lange syndrome or Noonan syndrome, such as a deletion of the short arm of chromosome 18p caused by Y/18 translocation.[11, 12] Zouboulis et al even claim that the LAMA1 gene is involved[13] ; however, Klein et al propose a 12q deletion as the cause of the condition.[14] A patient with Noonan syndrome and ulerythema ophryogenes associated with an SOS1 mutation has been described.[15]  Whole exome sequencing identified a unique homozygous missense variant on the lipoprotein receptor-related protein 1 gene as pathogenic, at least in cases of autosomal recessive keratosis pilaris atrophicans,[16] of which ulerythema ophryogenes can be viewed as a subtype.

Epidemiology

Frequency

Worldwide incidence rates are not known.

Race

Individuals of all races can be affected.

Sex

This condition can affect males and females.

Age

Children and young adults are most commonly affected with this condition.

Prognosis

The disease tends to improve over time. However, this disorder may be the first sign of Noonan syndrome, which is important to recognize owing to its cardiovascular defects.[17]

Patient Education

Young patients should be encouraged to live with this mild esthetic shortcoming.

History

The parents usually note erythema and tiny keratotic papules on the lateral parts of the eyebrows during early childhood. Similar lesions may develop on the lateral aspects of the front and on the cheeks. Later, atrophy and loss of eyebrows may ensue. Sometimes, discrete follicular papules appear; follicular papules may also be present on the extensor sites of the arms and the thighs.

Physical Examination

Erythema with slight follicular hyperkeratosis appears on the cheeks and lateral aspects of the eyebrows. The scalp may also be involved. The affected areas may feel rough on delicate palpation.

A generalized facial erythema with scattered open and closed comedones and milia may be present. Rarely, similar lesions may be seen on the extensor surfaces of the arms and legs.

Hyperkeratotic follicular plugs with surrounding erythema that eventually evolves into coalescent follicular depressions in a honeycombed or worm-eaten pattern may be present in ulerythema of the cheeks, also known as atrophoderma vermiculatum. From the cheeks, ulerythema may extend to the ears and forehead.

The condition usually improves as the patient ages, but a loss of the lateral aspects of the eyebrows is possible, and scars may develop in the affected areas.

Complications

Scars may eventually develop at the sites of the hyperkeratotic papules.

Laboratory Studies

No laboratory test, except histopathologic examination, is diagnostic.

Histologic Findings

In the early phase, pilosebaceous follicles filled with keratotic plugs and a mild perifollicular inflammatory infiltrate are observed. Cystic dilatation of the hair follicles may be evident on the cheeks. Later, atrophy of both hair follicles and sebaceous glands, as well as a dermal fibrosis, may appear.

Staging

Two stages may eventually be observed: an early stage characterized by follicular hyperkeratosis and a late stage with some evidence of fibrosis and atrophy.

Medical Care

The disease often improves with age. The risk-benefit correlation does not support the use of systemic retinoids for the treatment of ulerythema ophryogenes.

Mild keratolytics, such as lactic acid 5%, urea 5%, or salicylic acid 2-5%, may be interchanged with cold creams, while low-potency corticosteroids may also be applied for short periods. Topical retinoid therapy may be worth trying.[26]

Sun protection creams are recommended when sun exposure is anticipated because frequent exposure to UV radiation exacerbates ulerythema ophryogenes. Local retinoids may not be effective.

Surgical Care

Successful treatment with carbon dioxide laser was reported in 2 patients, and the 585-nm pulsed dye lasers seemed efficient[27] ; however, in general, the treatment is rather unrewarding. Treatment with intense pulsed light may be worth considering.[28] Keratosis pilaris rubra and keratosis pilaris atrophicans faciei may be treated with good results using pulsed dye laser at 595-nm wavelength.[29]

Diet

No special diet is necessary.

Activity

Excessive sunlight should be avoided.

Prevention

Patients with ulerythema ophryogenes should not be exposed to the sun without UV protection.

Long-Term Monitoring

Regular checkups are recommended for patients with this condition.

Author

Camila K Janniger, MD, Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Specialty Editors

Michael J Wells, MD, FAAD, Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

James J Nordlund, MD, Professor Emeritus, Department of Dermatology, University of Cincinnati College of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Aleksej Kansky, MD, PhD, to the development and writing of this article.

References

  1. Burnett JW, Schwartz MF, Berberian BJ. Ulerythema ophryogenes with multiple congenital anomalies. J Am Acad Dermatol. 1988 Feb. 18(2 Pt 2):437-40. [View Abstract]
  2. Gómez Centeno P, Rosón E, Peteiro C, Mercedes Pereiro M, Toribio J. Rubinstein--Taybi syndrome and ulerythema ophryogenes in a 9-year-old boy. Pediatr Dermatol. 1999 Mar-Apr. 16(2):134-6. [View Abstract]
  3. Snell JA, Mallory SB. Ulerythema ophryogenes in Noonan syndrome. Pediatr Dermatol. 1990 Mar. 7(1):77-8. [View Abstract]
  4. Morton CM, Bhate C, Janniger CK, Schwartz RA. Ulerythema ophryogenes: updates and insights. Cutis. 2014 Feb. 93(2):83-7. [View Abstract]
  5. Luria RB, Conologue T. Atrophoderma vermiculatum: a case report and review of the literature on keratosis pilaris atrophicans. Cutis. 2009 Feb. 83(2):83-6. [View Abstract]
  6. Turegano MM, Sperling LC. Lichenoid folliculitis: A unifying concept. J Cutan Pathol. 2017 Mar 26. [View Abstract]
  7. Carvalho CA, Carvalho AV, Kiss A, Paskulin G, Götze FM. Keratosis pilaris and ulerythema ophryogenes in a woman with monosomy of the short arm of chromosome 18. An Bras Dermatol. 2011 Jul-Aug. 86(4 Suppl 1):S42-5. [View Abstract]
  8. Liakou AI, Esteves de Carvalho AV, Nazarenko LP. Trias of keratosis pilaris, ulerythema ophryogenes and 18p monosomy: Zouboulis syndrome. J Dermatol. 2014 May. 41(5):371-6. [View Abstract]
  9. Siegel DH, Mann JA, Krol AL, Rauen KA. Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development. Br J Dermatol. 2012 Mar. 166(3):601-7. [View Abstract]
  10. Bessis D, Morice-Picard F, Bourrat E, et al. Dermatological manifestations in cardiofaciocutaneous syndrome: a prospective multicentric study of 45 mutation-positive patients. Br J Dermatol. 2019 Jan. 180 (1):172-180. [View Abstract]
  11. Nazarenko SA, Ostroverkhova NV, Vasiljeva EO, Nazarenko LP, Puzyrev VP, Malet P, et al. Keratosis pilaris and ulerythema ophryogenes associated with an 18p deletion caused by a Y/18 translocation. Am J Med Genet. 1999 Jul 16. 85(2):179-82. [View Abstract]
  12. Zouboulis CC, Stratakis CA, Rinck G, Wegner RD, Gollnick H, Orfanos CE. Ulerythema ophryogenes and keratosis pilaris in a child with monosomy 18p. Pediatr Dermatol. 1994 Jun. 11(2):172-5. [View Abstract]
  13. Zouboulis CC, Stratakis CA, Gollnick HP, Orfanos CE. Keratosis pilaris/ulerythema ophryogenes and 18p deletion: is it possible that the LAMA1 gene is involved?. J Med Genet. 2001 Feb. 38(2):127-8. [View Abstract]
  14. Klein OD, Cotter PD, Schmidt AM, et al. Interstitial deletion of chromosome 12q: genotype-phenotype correlation of two patients utilizing array comparative genomic hybridization. Am J Med Genet A. 2005 Nov 1. 138(4):349-54. [View Abstract]
  15. Li K, Ann Thomas M, Haber RM. Ulerythema ophryogenes, a rarely reported cutaneous manifestation of noonan syndrome: case report and review of the literature. J Cutan Med Surg. 2013 May-Jun. 17(3):212-8. [View Abstract]
  16. Klar J, Schuster J, Khan TN, Jameel M, Mäbert K, Forsberg L, et al. Whole exome sequencing identifies LRP1 as a pathogenic gene in autosomal recessive keratosis pilaris atrophicans. J Med Genet. 2015 Sep. 52 (9):599-606. [View Abstract]
  17. Guidry JA, Rees A, Chan AJ, Shuja F, Hsu S. Ulerythema ophryogenes and Noonan syndrome. Dermatol Online J. 2013 Feb 15. 19(2):14. [View Abstract]
  18. Lee YC, Son SJ, Han TY, Lee JH. A Case of Atrophoderma Vermiculatum Showing a Good Response to Topical Tretinoin. Ann Dermatol. 2018 Feb. 30 (1):116-118. [View Abstract]
  19. Volks N, Fölster-Holst R. Erythromelanosis follicularis faciei--a variant of keratosis pilaris?. J Dtsch Dermatol Ges. 2015 Jan. 13 (1):51-4. [View Abstract]
  20. Arif T, Adil M, Amin SS, Tahseen M, Dorjay K, Mohtashim M, et al. Erythromelanosis follicularis faciei et colli: A clinicoepidemiologic study. Pediatr Dermatol. 2018 Jan. 35 (1):e70-e71. [View Abstract]
  21. Hodak E, Amitay-Laish I, Atzmony L, Prag-Naveh H, Yanichkin N, Barzilai A, et al. New insights into folliculotropic mycosis fungoides (FMF): A single-center experience. J Am Acad Dermatol. 2016 May 28. [View Abstract]
  22. Shimizu A, Hattori M, Takeuchi Y, Ishikawa O. Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib. J Dermatol. 2016 Mar 30. [View Abstract]
  23. Quintana Castanedo L, Sánchez Orta A, Maseda Pedrero R, Santos Simarro F, Palomares Bralo M, Feito Rodríguez M, et al. Skin and nails abnormalities in a patient with ZTTK syndrome and a de novo mutation in SON. Pediatr Dermatol. 2020 Feb 11. [View Abstract]
  24. Zegarska B, Kallas D, Schwartz RA, Czajkowski R, Uchanska G, Placek W. Graham-Little syndrome. Acta Dermatovenerol Alp Panonica Adriat. 2010 Oct. 19(3):39-42. [View Abstract]
  25. Dajani ZA, Kerns MJ, Mutasim DF. Unilateral keratosis pilaris atrophicans faciei mimicking follicular mucinosis. J Am Acad Dermatol. 2011 May. 64(5):e71-2. [View Abstract]
  26. Layton AM, Cunliffe WJ. A case of ulerythema ophryogenes responding to isotretinoin. Br J Dermatol. 1993 Nov. 129(5):645-6. [View Abstract]
  27. Handrick C, Alster TS. Laser treatment of atrophoderma vermiculata. J Am Acad Dermatol. 2001 Apr. 44(4):693-5. [View Abstract]
  28. Rodriguez-Lojo R, Pozo JD, Barja JM, et al. Keratosis pilaris atrophicans: treatment with intense pulsed light in four patients. J Cosmet Laser Ther. 2010 Aug. 12(4):188-90. [View Abstract]
  29. Alcántara González J, Boixeda P, Truchuelo Díez MT, Fleta Asín B. Keratosis pilaris rubra and keratosis pilaris atrophicans faciei treated with pulsed dye laser: report of 10 cases. J Eur Acad Dermatol Venereol. 2011 Jun. 25(6):710-4. [View Abstract]